PT - JOURNAL ARTICLE AU - Dickens, Alex M. AU - Sen, Partho AU - Kempton, Matthew J AU - Barrantes-Vidal, Neus AU - Iyegbe, Conrad AU - Nordentoft, Merete AU - Pollak, Thomas AU - Riecher-Rössler, Anita AU - Ruhrmann, Stephan AU - Sachs, Gabriele AU - Bressan, Rodrigo AU - Krebs, Marie-Odile AU - de Haan, Lieuwe AU - van der Gaag, Mark AU - Valmaggia, Lucia AU - Hyötyläinen, Tuulia AU - Orešič, Matej AU - McGuire, Philip AU - , TI - Dysregulated lipid metabolism precedes onset of psychosis in people at clinical high risk AID - 10.1101/2020.01.30.20019851 DP - 2020 Jan 01 TA - medRxiv PG - 2020.01.30.20019851 4099 - http://medrxiv.org/content/early/2020/02/03/2020.01.30.20019851.short 4100 - http://medrxiv.org/content/early/2020/02/03/2020.01.30.20019851.full AB - A key clinical challenge in the management of individuals at clinical high risk for psychosis (CHR) is that it is difficult to predict their future clinical outcomes. Here, we investigated if the levels of circulating molecular lipids are related to adverse clinical outcomes in this group. Serum lipidomic analysis was performed in 263 CHR individuals and 51 healthy controls (HC), who were then clinically monitored for up to five years. Machine learning was used to identify lipid profiles that discriminated between CHR subjects and HC, and between subgroups of CHR subjects with distinct clinical outcomes. At baseline, compared to HC, CHR subjects (independent of outcome) had higher levels of triacylglycerols (TGs) with a low acyl carbon number and a double bond count, as well as higher levels of lipids in general. CHR subjects who subsequently developed psychosis (n=50) were distinguished from those that did not (n=213) on the basis of lipid profile at baseline, using a model with an AUC = 0.81 (95% CI = 0.69-0.93). CHR subjects who became psychotic had lower levels of ether phospholipids than CHR individuals who did not (p<0.01). Collectively, these data suggest that lipidomic abnormalities predate the onset of psychosis, and that blood lipidomic measures may be useful in predicting which CHR individuals are most likely to develop psychosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has received funding from the European Union’s Seventh Framework Programme for projects EU-GEI – ‘European network of national schizophrenia networks studying Gene-Environment Interactions’ (HEALTH-F2-2010-241909) and METSY – ‘Neuroimaging platform for characterization of metabolic co-morbidities in psychotic disorders’ (no. 602478). Additional support was provided by a Medical Research Council Fellowship to M. Kempton (grant MR/J008915/1) and grants from the Ministerio de Ciencia, Innovación e Universidades (PSI2017-87512-C2-1-R) and Generalitat de Catalunya (2017SGR1612 & ICREA Academia Award) to N. Barrantes-Vidal.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReasonable requests for access to the data of this study will be carefully considered by the EU-GEI High Risk Study publication committee.